Efron D, Jarman F, Barker M
Centre for Community Child Health and Ambulatory Paediatrics, Royal Children's Hospital, Melbourne, Victoria, Australia.
Pediatrics. 1997 Oct;100(4):662-6. doi: 10.1542/peds.100.4.662.
To compare the side effect profiles of methylphenidate (MPH) and dexamphetamine (DEX) in children with attention deficit hyperactivity disorder (ADHD), as well as to determine which symptoms are genuine adverse effects of stimulant medication, as opposed to aspects of the child's underlying behavioral phenotype.
Double-blind, crossover study.
Pediatric teaching hospital ambulatory behavior clinic.
A total of 125 children with ADHD with a mean age of 104.8 months.
Subjects received DEX (0.15 mg/kg/dose) and MPH (0.3 mg/kg/dose) twice a day for 2 weeks each in a randomized order.
The Barkley Side Effects Rating Scale (17 symptoms; 0 = absent, severity rated from 1 to 9) was completed by parents at baseline and at the completion of each trial fortnight.
Subjects' parents reported a significantly greater mean number (8.19) and mean severity (4.08) of "side effects" before commencing the trial than during the MPH period (number 7.19; severity 3.24), but not the DEX period (number 7.64, severity 3.73). The mean severity (but not mean number) was greater on DEX than on MPH. DEX caused more severe insomnia and appetite suppression compared with the baseline rating. Appetite suppression was the only item rated more severe on MPH than at baseline. Six side effects were significantly more severe on DEX than MPH: insomnia, irritability, proneness to crying, anxiousness, sadness/unhappiness, and nightmares. None were more severe on MPH than DEX. Overall, both MPH and DEX were well tolerated by most subjects, with only four subjects discontinuing the trial period because of severe adverse effects (2 -1.6%- on each stimulant).
Many symptoms commonly attributed to stimulant medication are actually preexisting characteristics of children with ADHD and improve with stimulant treatment. At the doses investigated, both DEX and MPH caused appetite suppression, and DEX caused insomnia. Negative emotional symptoms were more severe on DEX than MPH.
比较哌甲酯(MPH)和右旋苯丙胺(DEX)在注意缺陷多动障碍(ADHD)儿童中的副作用情况,并确定哪些症状是刺激性药物真正的不良反应,而非儿童潜在行为表型的表现。
双盲交叉研究。
儿科教学医院门诊行为诊所。
共125名ADHD儿童,平均年龄104.8个月。
受试者随机接受DEX(0.15mg/kg/剂量)和MPH(0.3mg/kg/剂量),每日两次,各为期2周。
在基线期以及每个试验两周结束时,由家长完成巴克莱副作用评定量表(17项症状;0=无,严重程度从1至9评定)。
受试者家长报告,在试验开始前“副作用”的平均数量(8.19)和平均严重程度(4.08)显著高于MPH治疗期(数量7.19;严重程度3.24),但不高于DEX治疗期(数量7.64,严重程度3.73)。DEX的平均严重程度(而非平均数量)高于MPH。与基线评定相比,DEX导致更严重的失眠和食欲抑制。食欲抑制是MPH治疗时唯一比基线时评定更严重的项目。有6项副作用在DEX治疗时比MPH更严重:失眠、易怒、易哭、焦虑、悲伤/不开心和噩梦。没有副作用在MPH治疗时比DEX更严重。总体而言,大多数受试者对MPH和DEX耐受性良好,只有4名受试者因严重不良反应而中断试验期(每种兴奋剂各2名,占1.6%)。
许多通常归因于刺激性药物的症状实际上是ADHD儿童预先存在的特征,且会随着刺激性药物治疗而改善。在所研究的剂量下,DEX和MPH均导致食欲抑制,且DEX导致失眠。DEX导致的负面情绪症状比MPH更严重。